Displaying drugs 10776 - 10800 of 11900 in total
Tertatolol
Tertatolol is a beta blocker.
Experimental
Matched Description: … Tertatolol is a beta blocker. …
IRX-5183
Investigational
OM85
OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.
Investigational
Matched Description: … OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity …
VTP-201227
VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. It is being developed by Vitae Pharmaceuticals.
Investigational
Matched Description: … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment …
Latrunculin B
Latrunculin B is a 14-membered macrolide attached to 2-thiazolidinone moiety, isolated from Red Sea sponge Latrunculia magnifica.
Experimental
Matched Description: … Latrunculin B is a 14-membered macrolide attached to 2-thiazolidinone moiety, isolated from Red Sea sponge …
Solithromycin
Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.
Investigational
Matched Description: … Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired …
Navicixizumab
Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Investigational
Matched Description: … Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab …
Pegapamodutide
Pegapamodutide is under investigation in clinical trial NCT02188303 (A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants).
Investigational
Matched Description: … Pegapamodutide is under investigation in clinical trial NCT02188303 (A Study of LY2944876 in Healthy …
TAS-116
TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid Tumors).
Investigational
Matched Description: … TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid …
LY-2623091
LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants With High Blood Pressure).
Investigational
Matched Description: … LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants …
Centhaquine
Centhaquine is under investigation in clinical trial NCT04045327 (Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock).
Investigational
Matched Description: … Centhaquine is under investigation in clinical trial NCT04045327 (Efficacy of PMZ-2010 (Centhaquine) a …
E59
E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. It was developed by Sixal Inc.
Investigational
Matched Description: … E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. …
Epaminurad
Epaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients).
Investigational
Matched Description: … Epaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of …
Rezpegaldesleukin
Rezpegaldesleukin is under investigation in clinical trial NCT04433585 (A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)).
Investigational
Matched Description: … Rezpegaldesleukin is under investigation in clinical trial NCT04433585 (A Study of LY3471851 in Adults …
Varespladib methyl
Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
Investigational
Fasinumab
Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population. NGF was first discovered...
Investigational
Matched Description: … Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). …
BOS172722
BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. Normally, Mps1 supports the proper division of cancer cells, ensuring survival and replication. The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment,...
Experimental
Matched Description: … BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential …
Terevalefim
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Matched Description: … Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a …
VP025
VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function. It is being developed to...
Investigational
Matched Description: … It is considered to be a systemic anti-inflammatory and neuroprotective agent. ... VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol ... developed to target the chronic inflammation within the central nervous system that is associated with a …
C31G
C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV).
Investigational
Matched Description: … C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative ... bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a …
IDD-1
Lipids promote the fusion of liposomes to cells. Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.
Investigational
Matched Description: … Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor ... As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related …
OSI-7904L
OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
Investigational
Matched Description: … gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). ... OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced …
Nisoxetine
Nisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. It has been used to research obesity and energy balance, and exerts some local analgesia effects.
Experimental
Matched Description: … Nisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. ... originally investigated as an antidepressant but has no current clinical applications aside from being a …
DOTMP SM-153
Investigational
KAI-1455
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and hip replacement and may protect against renal injury associated with contrast media. Several studies...
Investigational
Matched Description: … KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury ... Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods ... In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to …
Displaying drugs 10776 - 10800 of 11900 in total